Literature DB >> 11295574

Multiple endocrine neoplasia type 1: new clinical and basic findings.

D H Schussheim1, M C Skarulis, S K Agarwal, W F Simonds, A L Burns, A M Spiegel, S J Marx.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) provides a prime example of how a rare disease can advance our understanding of basic cell biology, neoplasia and common endocrine tumors. MEN1 is expressed mainly as parathyroid, enteropancreatic neuroendocrine, anterior pituitary and foregut carcinoid tumors. It is an autosomal dominant disease caused by mutation of the MEN1 gene. Since its identification, the MEN1 gene has been implicated in many common endocrine and non-endocrine tumors. This is a brief overview of recent scientific advances relating to MEN1, including newly recognized clinical features that are now better characterized by genetic analysis, insights into the function of the MEN1-encoded protein menin, and refined recommendations for mutation testing and tumor screening, which highlight our increasing understanding of this complex syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295574     DOI: 10.1016/s1043-2760(00)00372-6

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  49 in total

1.  MEN1 family with a novel frameshift mutation.

Authors:  V Nuzzo; L Tauchmanová; A Falchetti; A Faggiano; F Marini; S Piantadosi; M L Brandi; L Leopaldi; A Colao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

Review 2.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

3.  Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Maria A Kouvaraki; Suzanne E Shapiro; Gilbert J Cote; Jeffrey E Lee; James C Yao; Steven G Waguespack; Robert F Gagel; Douglas B Evans; Nancy D Perrier
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 4.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

5.  Menin induces apoptosis in murine embryonic fibroblasts.

Authors:  Robert W Schnepp; Hua Mao; Stephen M Sykes; Wei-Xing Zong; Albert Silva; Ping La; Xianxin Hua
Journal:  J Biol Chem       Date:  2003-12-18       Impact factor: 5.157

6.  Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1).

Authors:  Terry C Lairmore; Linda D Piersall; Mary K DeBenedetti; William G Dilley; Matthew G Mutch; Alison J Whelan; Barbara Zehnbauer
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

7.  Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics.

Authors:  D Scarpelli; L D'Aloiso; F Arturi; A Scillitani; I Presta; M Bisceglia; C Cristofaro; D Russo; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

8.  Direct binding of DNA by tumor suppressor menin.

Authors:  Ping La; Albert C Silva; Zhaoyuan Hou; Haoren Wang; Robert W Schnepp; Nieng Yan; Yigong Shi; Xianxin Hua
Journal:  J Biol Chem       Date:  2004-08-24       Impact factor: 5.157

9.  Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1.

Authors:  Caroline L Lopez; Max B Albers; Carmen Bollmann; Jerena Manoharan; Jens Waldmann; Volker Fendrich; Detlef K Bartsch
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

10.  Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age?

Authors:  Anita Skandarajah; Anne Barlier; Nathalie Morlet-Barlat; Frederic Sebag; Alain Enjalbert; Bernard Conte-Devolx; Jean-François Henry
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.